A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG

Running, not enrolling · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Phosphomannomutase 2 Deficiency, PMM2-CDG

In brief

This study is evaluating the safety, effectiveness, and how the body absorbs, distributes, and eliminates GLM101, for participants with PMM2-CDG, including children, adolescents, and adults. Researchers will compare participants receiving GLM101 to those receiving a placebo to see if GLM101 improves symptoms of PMM2-CDG. The study includes two treatment parts: a 24-week double blind placebo-controlled treatment period (Part A), and a 24-week open-label phase where every participant will receive GLM101(Part B).

Key facts

Study ID
NCT06892288
Run by
Glycomine, Inc.
People needed
50
Starts
2025-07-09
Expected to finish
2027-04-30
Last updated by the study team
2026-02-27

Who can join

Age: 4 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.